{
    "Trade/Device Name(s)": [
        "Abbott Phenobarbital Assay"
    ],
    "Submitter Information": "Thermo Fisher Scientific, Clinical Diagnostics Division",
    "510(k) Number": "K123271",
    "Predicate Device Reference 510(k) Number(s)": [
        "K993031"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DLZ"
    ],
    "Summary Letter Date": "February 27, 2013",
    "Summary Letter Received Date": "March 18, 2013",
    "Submission Date": "October 17, 2012",
    "Regulation Number(s)": [
        "21 CFR 862.3660"
    ],
    "Regulation Name(s)": [
        "Phenobarbital test system"
    ],
    "Analyte Class(es)": [
        "toxicology",
        "tdm"
    ],
    "Analyte(s)": [
        "Phenobarbital"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Glass tube",
        "Plastic tube",
        "Serum separator tube (SST) in plastic",
        "Sodium fluoride/potassium oxalate in plastic",
        "Sodium heparin in plastic",
        "Sodium heparin in glass",
        "Lithium heparin in plastic with or without gel",
        "K3 EDTA in glass",
        "K3 EDTA in plastic",
        "K2 EDTA in plastic",
        "Sodium citrate in plastic",
        "Sodium citrate in glass"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT cSystems"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous particle-enhanced turbidimetric inhibition immunoassay (PETINIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Agglutination inhibition"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for the Abbott Phenobarbital Assay, an in vitro immunoassay for quantitative measurement of phenobarbital in human serum or plasma using ARCHITECT cSystems.",
    "Indications for Use Summary": "For in vitro quantitative measurement of phenobarbital in human serum or plasma to aid in the diagnosis and treatment of phenobarbital overdose and monitoring therapy.",
    "fda_folder": "Toxicology"
}